Novartis AG (LON:0K9E)

Market Cap	171.21B
Revenue (ttm)	41.19B
Net Income (ttm)	9.95B
Shares Out	n/a
EPS (ttm)	4.94
PE Ratio	17.20
Forward PE	14.24
Dividend	2.61 (2.18%)
Ex-Dividend Date	Mar 12, 2025

Volume	578
Average Volume	313
Open	118.80
Previous Close	120.53
Day's Range	118.80 - 119.89
52-Week Range	96.11 - 120.72
Beta	n/a
RSI	58.02
Earnings Date	Jul 17, 2025

About Novartis AG

Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Re...

• Industry: Pharmaceutical Preparations
• Founded: 1996
• Employees: 75,883
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0K9E

Financial Performance

In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.

Financial numbers in USD